Lipoprav (Pravastatin Sodium)

Pravastatin sodium blocks the enzyme HMG‑CoA reductase in the liver, the key step in cholesterol production. By decreasing hepatic cholesterol synthesis, the liver increases the number of LDL receptors, which clear more LDL cholesterol from the bloodstream, resulting in lower plasma cholesterol levels.

The appropriate dose of Lipoprav is determined by the prescribing healthcare professional based on the patient’s cholesterol levels, overall cardiovascular risk, age, kidney function, and other individual factors. Patients should follow the dosage instructions provided by their prescriber.

Pravastatin is generally not recommended during pregnancy or while breastfeeding because the safety profile has not been established for these populations. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative lipid‑lowering strategies with their healthcare provider.

To request Lipoprav, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lipoprav (pravastatin) is a hydrophilic statin with a lower potential for drug‑drug interactions compared with some lipophilic statins such as simvastatin. It is often chosen for patients who require a moderate intensity lipid‑lowering effect and who may be taking medications that interact with CYP3A4‑metabolized statins.

Lipoprav tablets should be stored at room temperature, below 25 °C (77 °F). Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Lipoprav is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

The most serious adverse reactions include rhabdomyolysis, a severe breakdown of muscle tissue that can lead to kidney failure, and hepatotoxicity, indicated by significant elevations in liver enzymes. Patients should report unexplained muscle pain, weakness, or dark urine promptly.

Lipoprav should be avoided in individuals with known hypersensitivity to pravastatin or any component of the formulation, active liver disease, unexplained persistent elevations in hepatic transaminases, or in patients taking contraindicated medications such as certain strong CYP3A4 inhibitors.